Krystal Biotech, Inc. $KRYS Stake Cut by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 8.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 47,941 shares of the company’s stock after selling 4,680 shares during the period. Russell Investments Group Ltd.’s holdings in Krystal Biotech were worth $15,943,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of KRYS. Heritage Family Offices LLP purchased a new position in shares of Krystal Biotech during the 3rd quarter worth $25,000. Silvant Capital Management LLC acquired a new position in shares of Krystal Biotech during the 2nd quarter valued at about $30,000. Western Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $34,000. USA Financial Formulas purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $44,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Krystal Biotech in the second quarter valued at about $46,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KRYS. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. The Goldman Sachs Group initiated coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They issued a “buy” rating and a $441.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $361.00 price target on shares of Krystal Biotech in a research note on Thursday, October 15th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Citigroup reduced their price target on shares of Krystal Biotech from $416.00 to $412.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $375.00.

Check Out Our Latest Analysis on KRYS

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by insiders.

Krystal Biotech Stock Up 0.2%

Shares of Krystal Biotech stock opened at $315.82 on Friday. The firm has a market cap of $9.36 billion, a PE ratio of 42.79 and a beta of 0.56. Krystal Biotech, Inc. has a 52 week low of $203.17 and a 52 week high of $382.54. The business’s fifty day simple moving average is $323.25 and its 200-day simple moving average is $310.27.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. The firm had revenue of $127.34 million during the quarter, compared to the consensus estimate of $125.77 million. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. As a group, equities analysts expect that Krystal Biotech, Inc. will post 7.74 earnings per share for the current year.

Krystal Biotech Company Profile

(Free Report)

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.

Recommended Stories

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).

Institutional Ownership by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.